LONDON, July 05, 2023 (GLOBE NEWSWIRE) Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused.
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from.
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical trial support target drug profile • O.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.